Augenzentrum Prof. Dr. Koch GmbH
- Address
- lock Available on a paid plan
Augenzentrum Prof. Dr. Koch GmbH - Advanced Retinal Disease Research Center
Augenzentrum Prof. Dr. Koch GmbH is a leading ophthalmologic research center with specialized expertise in age-related macular degeneration (AMD) and innovative retinal therapies. The center demonstrates exceptional capabilities in evaluating cutting-edge drug delivery systems and novel therapeutic approaches for vision-threatening retinal conditions.
- Neovascular age-related macular degeneration (nAMD) with focus on sustained-release delivery systems including the Port Delivery System with ranibizumab
- Geographic atrophy secondary to AMD, investigating complement inhibition strategies with subcutaneous pozelimab and cemdisiran
- Advanced intravitreal therapeutics including faricimab bispecific antibody and gene therapy approaches with 4D-150
- Long-term safety and efficacy assessments of extended dosing intervals and novel drug formulations
The center's research portfolio emphasizes best-corrected visual acuity (BCVA) outcomes and durability of treatment responses. Their participation in pivotal Phase 3 trials demonstrates commitment to advancing both wet and dry forms of AMD treatment, from traditional intravitreal injections to revolutionary implantable systems and gene therapy vectors designed to provide sustained therapeutic benefits with reduced treatment burden for patients.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 4 by active trials.
- 1F. Hoffmann-La Roche AG1active
lock +3 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1F. Hoffmann-La Roche AG2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Augenzentrum Prof. Dr. Koch GmbH
lock Showing 1 of 5 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy and Safety Evaluation of Xelafaslatide (ONL1204) in Geographic Atrophy Secondary to Age-related Macular Degeneration: A Phase 2 Randomized Controlled Trial | ONL Therapeutics Inc. | Phase II | Recruiting | Apr 2026 | — |
IMP list
lock Showing 1 of 7 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Aflibercept | 1 | Unknown | 2025-12-09 | 2025-12-09 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.